RT Book, Section
A1 Awan, Farrukh T.
A1 Byrd, John C.
A2 Kaushansky, Kenneth
A2 Lichtman, Marshall A.
A2 Prchal, Josef T.
A2 Levi, Marcel M.
A2 Press, Oliver W.
A2 Burns, Linda J.
A2 Caligiuri, Michael
SR Print(0)
ID 1149102369
T1 Chronic Lymphocytic Leukemia
T2 Williams Hematology, 9e
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 9780071833004
LK hemonc.mhmedical.com/content.aspx?aid=1149102369
RD 2024/04/24
AB SUMMARYChronic  lymphocytic  leukemia  is  a  malignancy  of  mature  B  cells  characterized  by  progressive  lymphocytosis,  lymphadenopathy,  splenomegaly,  and  cytopenias.  The  progressive  accumulation  of  leukemic  B  cells  is  a  consequence  of  defective  apoptosis  and  survival  signals  derived  from  the  microenvironment.  Progressive  disease  results  in  dysregulation  of  the  cellular  and  humoral  components  of  the  effector  immune  system  with  a  resultant  increase  in  the  incidence  of  infectious  complications,  which  constitutes  the  leading  cause  of  morbidity  and  mortality  in  this  disease.  Significant  therapeutic  advances  have  been  realized  in  recent  years,  especially  with  the  development  of  well-tolerated  targeted  antibodies  and  kinase  inhibitors.  Although  not  curative,  these  therapies  have  resulted  in  significant  improvements  in  patient  outcomes  with  substantial  increases  in  progression-free  and  overall  survival  intervals.  Multiple  novel  agents  are  also  in  development  with  the  potential  to  alter  the  treatment  paradigms  for  this  disease  and  ultimately  to  affect  a  cure.